Objective:

To identify blood metabolites associated with future cardiac disease progression in people with chronic Chagas disease.

Approach:

• Study samples: Researchers analyzed stored serum samples from 72 patients with chronic Chagas disease in Bolivia.
• Metabolite analysis: Liquid chromatography–mass spectrometry was used to identify metabolic differences associated with subsequent cardiac deterioration.

Key Findings:

• Among patients initially without cardiac involvement, 15 developed more advanced disease during follow-up, while 48 remained stable.
• Eight individual metabolites were associated with future progression.
• Combining metabolites produced 45 candidate biomarker panels; 10 had at least 60% sensitivity and 90% specificity.
• Several predictive molecules were lipid-related.

Interpretation:

The study authors report that blood-metabolite patterns may help distinguish patients at risk of cardiac progression from those likely to remain stable. The approach measures changes in the patient's metabolism rather than detecting the parasite.

Limitations:

• The study was relatively small.
• The biomarkers require validation in larger, geographically diverse populations.
• Standardized testing methods and clinical utility must be established before routine diagnostic use.

Conclusion:

The authors state that, if validated, the biomarkers could support cardiac monitoring, treatment prioritization, and clinical trial design.

Sources:

• Article context; research published in Nature Communications